Title: County by county estimation of deaths averted, infections averted, and cost savings of overdose prevention health centers in the United States

Authors: Mike Sportiello, PhD[1], Rohith Palli MD/PhD [2]

1. Medical Scientist Training Program at the University of Rochester Medical Center. 601 Elmwood Avenue Rochester, NY 14642.
2. Internal Medicine Residency at the University of Rochester Medical Center. 601 Elmwood Avenue Rochester, NY 14642.

Abstract

Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection centers, are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s (Beletsky, Baker et al. 2018). Using CDC overdose deaths and United States Census Bureau population data, we estimate over 14,000 deaths could be averted between 2020 and 2022 if 1 out of 20 injections had taken place at an OPHC. At this rate, over 100 HIV transmissions and 57,000 Hepatitis C Virus transmissions would have been averted as well. Almost 20 billion dollars in discounted lifetime costs to treat those infections could have been saved as well. This data supports OPHCs as a viable public health intervention to avert deaths and avoid infections.

Introduction

Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection centers, are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s (Beletsky, Baker et al. 2018). Since this time, there have been reported overdoses, but no reported deaths in this supervised health care setting, as naloxone, an opioid overdose reversal agent as well as access to respiratory therapy like supplemental oxygen or ventilation is readily available. Other studies have focused on assessing the impact of an OPHC in their community, but no study has analyzed all United States counties and modeled the likely impact. In this analysis, we analyze how many deaths averted, infections averted, and the cost savings accrued had the county adopted OPHCs during this time.

Methods

Drug overdose deaths by month per county were accessed from the National Center for Health Statistics from 2020-2022. Population and age data were downloaded from the United States Census Bureau. County names were standardized. For this analysis, we estimated 1.5% of adults were people who injected drugs (PWID) per others' work (Bradley, Hall et al. 2023). For each PWID, we estimated 508.8 injections per year, or just under 1.5 injections per day per other's work (Bradley, Hall et al. 2023).

Deaths averted

Deaths averted was calculated by assuming the total number of injections stayed constant. Secondly, we assumed that deaths cannot occur after an injection in the OPHC, as no overdose death has ever occurred in an OPHC. The *injections that would occur at OPHC* was calculated by modeling 2.5%, 5%, 7.5%, or 10% of injections taking place at the OPHC. This led to the following calculation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * Overdose\ deaths = Deaths\ averted$$

With the fraction on the left simplifying to the frequency of total injections in the OPHC, multiplied by the number of deaths. If all the injections took place at the OPHC, the leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the whole left term would simplify to 0 and no deaths would be averted.

HCV transmissions averted

Hepatitis C virus (HCV) is a highly transmissible virus in the setting of shared needle use, leading to significant morbidity, mortality, and health expenditures. While curative therapy now exists, it is expensive and requires weeks-long adherence which is difficult for many who inject drugs as they are disproportionately housing insecure. Similar to deaths averted, due to the supply of sterile drug use equipment including needles and cottons, transmission of HCV has never been documented at an OPHC. Natural incidence of HCV within PWID varies widely, with studies with varying from 0.51 to 47

per 100 person years. For this analysis, we used a lower-end estimate of 10 per 100 person years (Gutfraind, Boodram et al. 2015), leading to the following equation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HCV\ incidence = HCV\ transmissions\ averted$$

HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is still a meaningful target of HIV transmission prevention efforts. Others have calculated the incidence of HIV transmission in groups of people who inject drugs, stratifying their use as low, medium, and high risk depending on factors including how often they share needles with people they know and alternatively with strangers (Jarlais, Bobashev et al. 2022). Using these incidences, we calculated HIV transmissions averted with the following equations:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ low\ risk = HIV\ transmissions\ averted$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ medium\ risk = HIV\ transmissions\ averted$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ high\ risk = HIV\ transmissions\ averted$$

Financial impact

Substantial health care dollars are spent treating preventable diseases. Infectious diseases are a particularly good target given how easily they can be prevented with appropriate education and low-cost materials. Others have estimated the discounted lifetime cost of an HIV infection to be $326,500 (Schackman, Fleishman et al. 2015). We calculated the discounted lifetime cost of an HIV infection with the following equation:

$$\$326{,}500 * averted\ HIV\ transmission = Discounted\ cost\ of\ an\ averted\ HIV\ infection$$

Similar work has been done to calculate the discounted lifetime cost of HCV, calculated to $320,328 (Liu, Barnett et al. 2016).

$$\$320{,}328 * averted\ HCV\ transmission = Discounted\ cost\ of\ an\ averted\ HCV\ infection$$

Finally, we calculated the total statistical costs of the lives to those who died from overdose, using the dollar mount the Federal Emergency Medical Agency $7,500,000 uses for their calculations, giving the following equation:

$$\$7{,}500{,}000 * Averted\ deaths = Statistical\ costs\ of\ deaths\ averted$$

Results

Deaths averted depends on what percentage of injections occur at the OPHC (Table 1). At the low end assuming 2.5% of injections occurred at OPHCs (1 injection out of 50, or one injection every 36 days [50/(508.8/365)]), over 7,000 deaths would have been averted. At the higher end, almost 29,000 deaths could have been averted. **Figure 1** maps the cumulative deaths averted assuming 5% of injections occurred at an OPHC.

Table 1: Summary table of results

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	7212.43	14424.85	21637.28	28849.70
HCV averted	28677.43	57354.86	86032.29	114709.72
HIV-low averted	57.35	114.71	172.06	229.42
HIV-medium averted	131.92	263.83	395.75	527.66
HIV-high averted	160.59	321.19	481.78	642.37
Discounted lifetime cost of infections	9.23E+09	1.85E+10	2.77E+10	3.69E+10
Cost of life	5.41E+10	1.08E+11	1.62E+11	2.16E+11
Total costs	6.33E+10	1.27E+11	1.90E+11	2.53E+11
Total costs (billions)	63.32	126.64	189.97	253.29

HCV infections averted range from just under 29,000 to just under 115,000 (**Figure 2**). Hundreds of HIV transmissions could have been averted (**Figure 3**). At least billions of dollars would have been saved, if not more with higher use, from relatively low rates of usage of OPHCs.

Even if OPHCs were only instituted in the top 50 most populous counties (Table 2) or the top 50 deaths per capita (Table 3), a substantial impact would be seen.

Table 2: Results for 50 most populous counties

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	2140.40	4280.80	6421.20	8561.60
HCV averted	8699.02	17398.04	26097.06	34796.08
HIV-low averted	17.40	34.80	52.19	69.59
HIV-medium averted	40.02	80.03	120.05	160.06
HIV-high averted	48.71	97.43	146.14	194.86
Discounted lifetime cost of infections	2.80E+09	5.60E+09	8.40E+09	1.12E+10
Cost of life	1.61E+10	3.21E+10	4.82E+10	6.42E+10
Total costs	1.89E+10	3.77E+10	5.66E+10	7.54E+10
Total costs (billions)	18.85	37.71	56.56	75.41

Table 3: Results for 50 counties with most deaths per capita

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	296.45	592.90	889.35	1185.80
HCV averted	350.41	700.83	1051.24	1401.66
HIV-low averted	0.70	1.40	2.10	2.80
HIV-medium averted	1.61	3.22	4.84	6.45
HIV-high averted	1.96	3.92	5.89	7.85
Discounted lifetime cost of infections	1.13E+08	2.26E+08	3.38E+08	4.51E+08
Cost of life	2.22E+09	4.45E+09	6.67E+09	8.89E+09
Total costs	2.34E+09	4.67E+09	7.01E+09	9.34E+09
Total costs (billions)	2.34	4.67	7.01	9.34

References

Beletsky, L., P. Baker, J. Arredondo, A. Emuka, D. Goodman-Meza, M. E. Medina-Mora, D. Werb, P. Davidson, J. J. Amon, S. Strathdee and C. Magis-Rodriguez (2018). "The global health and equity imperative for safe consumption facilities." Lancet **392**(10147): 553-554.

Bradley, H., E. W. Hall, A. Asher, N. W. Furukawa, C. M. Jones, J. Shealey, K. Buchacz, S. Handanagic, N. Crepaz and E. S. Rosenberg (2023). "Estimated Number of People Who Inject Drugs in the United States." Clin Infect Dis **76**(1): 96-102.

Gutfraind, A., B. Boodram, N. Prachand, A. Hailegiorgis, H. Dahari and M. E. Major (2015). "Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections." PLoS One **10**(9): e0137993.

Jarlais, D. D., G. Bobashev, J. Feelemyer and C. McKnight (2022). "Modeling HIV transmission among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the COVID-19 pandemic." Drug Alcohol Depend **238**: 109573.

Liu, S., P. G. Barnett, M. Holodniy, J. Lo, V. R. Joyce, R. Gidwani, S. M. Asch, D. K. Owens and J. D. Goldhaber-Fiebert (2016). "Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations." MDM Policy Pract **1**(1).

Schackman, B. R., J. A. Fleishman, A. E. Su, B. K. Berkowitz, R. D. Moore, R. P. Walensky, J. E. Becker, C. Voss, A. D. Paltiel, M. C. Weinstein, K. A. Freedberg, K. A. Gebo and E. Losina (2015). "The lifetime medical cost savings from preventing HIV in the United States." Med Care **53**(4): 293-301.

Figures

Title: County by county estimation of deaths averted, infections averted, and cost savings of overdose prevention health centers in the United States

Authors: Mike Sportiello, PhD[1], Rohith Palli MD/PhD [2]



Figure 1: Per county cumulative lives saved assuming 1/20 injections occurred at an OPHC.



Figure 2: Figure 1: Per county cumulative HCV transmissions averted assuming 1/20 injections occurred at an OPHC.



Figure 3: Figure 1: Per county cumulative HIV transmissions averted assuming 1/20 injections occurred at an OPHC according to 3 transmission dynamics: low, medium, or high.